BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Market Closed - BOERSE MUENCHEN 20:45:17 17/05/2024 BST | ||
| 1,067 EUR | +0.36% |
|
| Current month | -0.55% | ||
| 1 month | +14.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 1,067 | +0.36% |
| 16/05/24 | 1,063 | -4.19% |
| 15/05/24 | 1,109 | +8.05% |
| 14/05/24 | 1,027 | +2.00% |
| 13/05/24 | 1,007 | -1.88% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 08:45 pm
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD3T9Z |
| ISIN | DE000HD3T9Z7 |
| Date issued | 18/03/2024 |
| Strike | 1,400 $ |
| Maturity | 20/09/2024 (124 Days) |
| Parity | 1 : 1 |
| Emission price | 943.7 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,110 € |
|---|---|
| Lowest since issue | 820.4 € |
| Spread | 0.24 € |
| Spread % | 0.02% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- Certificat
